News | October 21, 2024
Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Subscribe To Our Newsletter & Stay Updated
